The North America Spinal Muscular Atrophy Treatment Market would witness market growth of 16.9% CAGR during the forecast period (2022-2028).
This genetic disorder kills specific nerve cells present in the spinal cord and brain called motor neurons. Motor neurons regulate skeletal muscle actions such as walking, swallowing, speaking, and breathing as well as movement in the legs, face, arms, chest, throat, and tongue. SMA comes in four different forms.
The most prevalent and serious form of SMA is type 1 and it is also known as Werdnig-Hoffmann illness or infantile-onset SMA. It typically manifests before the age of six months. SMA's Type 2 is a middle variant. Usually, between the ages of 6 and 18 months, symptoms become apparent. Children can sit unaided but cannot stand or walk unassisted.
SMA's Type 3 variant is further milder than the Type 2. It also goes by the name Kugelberg-Welander illness, and it appears to be muscular dystrophy after the age of 18 months. Children can walk on their own, but they can have trouble running, climbing stairs, or getting up from a chair. Type 4 is quite uncommon and it typically begins in adolescence, resulting in modest motor disability.
In this region, the SMA treatment are widely adopted because of its developed economy, rising health care costs, rising incidence of disorders linked to a sedentary lifestyle, and high acceptance of technologically advanced products. There are many uncommon diseases for which there is no FDA-approved medication. The treatment adoption in North America is further boosted by American reimbursement rules, particularly for the management of rare disorders like SMA.
The US market dominated the North America Spinal Muscular Atrophy Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $4,222 million by 2028. The Canada market is poised to grow at a CAGR of 19.5% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 18.5% during (2022 - 2028).
Based on Type, the market is segmented into Type 1, Type 2, Type 3 and Type 4. Based on Route of Administration, the market is segmented into Injection and Oral. Based on Treatment Type, the market is segmented into Drug and Gene Therapy. Based on Drug Type, the market is segmented into Spinraza, Zolgensma (AVXS-101), Evrysdi and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Spinal Muscular Atrophy Treatment Market is Estimated to reach $11.4 Billion by 2028, at a CAGR of 17.8%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Biogen, Inc., Novartis AG, Ionis Pharmaceuticals, Inc., PTC Therapeutics, Inc., NMD Pharma A/S, Scholar Rock, Inc. (Scholar Rock Holding Corporation), Cytokinetics, Inc., Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.), Astellas Pharma, Inc., and F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
Scope of the Study
Market Segments Covered in the Report:
By Type
By Route of Administration
By Treatment Type
- Drug
- Spinraza
- Zolgensma (AVXS-101)
- Evrysdi
- Others
- Gene Therapy
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Biogen, Inc.
- Novartis AG
- Ionis Pharmaceuticals, Inc.
- PTC Therapeutics, Inc.
- NMD Pharma A/S
- Scholar Rock, Inc. (Scholar Rock Holding Corporation)
- Cytokinetics, Inc.
- Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.)
- Astellas Pharma, Inc.
- F.Hoffmann-La Roche Ltd. (Genentech, Inc.)
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Spinal Muscular Atrophy Market, by Type
1.4.2 North America Spinal Muscular Atrophy Market, by Route of Administration
1.4.3 North America Spinal Muscular Atrophy Market, by Treatment Type
1.4.4 North America Spinal Muscular Atrophy Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Spinal Muscular Atrophy Market
Chapter 4. North America Spinal Muscular Atrophy Treatment Market by Type
4.1 North America Type 1 Market by Country
4.2 North America Type 2 Market by Country
4.3 North America Type 3 Market by Country
4.4 North America Type 4 Market by Country
Chapter 5. North America Spinal Muscular Atrophy Treatment Market by Route of Administration
5.1 North America Injection Market by Country
5.2 North America Oral Market by Country
Chapter 6. North America Spinal Muscular Atrophy Treatment Market by Treatment Type
6.1 North America Drug Market by Country
6.2 North America Spinal Muscular Atrophy Treatment Market by Drug Type
6.2.1 North America Spinraza Market by Country
6.2.2 North America Zolgensma (AVXS-101) Market by Country
6.2.3 North America Evrysdi Market by Country
6.2.4 North America Others Market by Country
6.3 North America Gene Therapy Market by Country
Chapter 7. North America Spinal Muscular Atrophy Treatment Market by Country
7.1 US Spinal Muscular Atrophy Treatment Market
7.1.1 US Spinal Muscular Atrophy Treatment Market by Type
7.1.2 US Spinal Muscular Atrophy Treatment Market by Route of Administration
7.1.3 US Spinal Muscular Atrophy Treatment Market by Treatment Type
7.1.3.1 US Spinal Muscular Atrophy Treatment Market by Drug Type
7.2 Canada Spinal Muscular Atrophy Treatment Market
7.2.1 Canada Spinal Muscular Atrophy Treatment Market by Type
7.2.2 Canada Spinal Muscular Atrophy Treatment Market by Route of Administration
7.2.3 Canada Spinal Muscular Atrophy Treatment Market by Treatment Type
7.2.3.1 Canada Spinal Muscular Atrophy Treatment Market by Drug Type
7.3 Mexico Spinal Muscular Atrophy Treatment Market
7.3.1 Mexico Spinal Muscular Atrophy Treatment Market by Type
7.3.2 Mexico Spinal Muscular Atrophy Treatment Market by Route of Administration
7.3.3 Mexico Spinal Muscular Atrophy Treatment Market by Treatment Type
7.3.3.1 Mexico Spinal Muscular Atrophy Treatment Market by Drug Type
7.4 Rest of North America Spinal Muscular Atrophy Treatment Market
7.4.1 Rest of North America Spinal Muscular Atrophy Treatment Market by Type
7.4.2 Rest of North America Spinal Muscular Atrophy Treatment Market by Route of Administration
7.4.3 Rest of North America Spinal Muscular Atrophy Treatment Market by Treatment Type
7.4.3.1 Rest of North America Spinal Muscular Atrophy Treatment Market by Drug Type
Chapter 8. Company Profiles
8.1 PTC Therapeutics, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.1.5.3 Approvals and Trials:
8.2 F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Approvals and Trials:
8.2.5.2 Acquisition and Mergers:
8.3 Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional & Segmental Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.4 Novartis AG
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Approvals and Trials:
8.4.5.2 Acquisition and Mergers:
8.5 Ionis Pharmaceuticals, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Research & Development Expenses
8.5.4 Recent strategies and developments:
8.5.4.1 Acquisition and Mergers:
8.6 Scholar Rock, Inc. (Scholar Rock Holding Corporation)
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Research & Development Expenses
8.7 Cytokinetics, Incorporated
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Research & Development Expenses
8.8 Astellas Pharma, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expense
8.9 Biogen, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expense
8.10. NMD Pharma A/S
8.10.1 Company Overview
8.10.2 Recent strategies and developments:
8.10.2.1 Geographical Expansions:
TABLE 1 North America Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
TABLE 2 North America Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
TABLE 3 North America Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
TABLE 4 North America Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
TABLE 5 North America Type 1 Market by Country, 2018 - 2021, USD Million
TABLE 6 North America Type 1 Market by Country, 2022 - 2028, USD Million
TABLE 7 North America Type 2 Market by Country, 2018 - 2021, USD Million
TABLE 8 North America Type 2 Market by Country, 2022 - 2028, USD Million
TABLE 9 North America Type 3 Market by Country, 2018 - 2021, USD Million
TABLE 10 North America Type 3 Market by Country, 2022 - 2028, USD Million
TABLE 11 North America Type 4 Market by Country, 2018 - 2021, USD Million
TABLE 12 North America Type 4 Market by Country, 2022 - 2028, USD Million
TABLE 13 North America Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 14 North America Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 15 North America Injection Market by Country, 2018 - 2021, USD Million
TABLE 16 North America Injection Market by Country, 2022 - 2028, USD Million
TABLE 17 North America Oral Market by Country, 2018 - 2021, USD Million
TABLE 18 North America Oral Market by Country, 2022 - 2028, USD Million
TABLE 19 North America Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
TABLE 20 North America Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
TABLE 21 North America Drug Market by Country, 2018 - 2021, USD Million
TABLE 22 North America Drug Market by Country, 2022 - 2028, USD Million
TABLE 23 North America Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 24 North America Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 25 North America Spinraza Market by Country, 2018 - 2021, USD Million
TABLE 26 North America Spinraza Market by Country, 2022 - 2028, USD Million
TABLE 27 North America Zolgensma (AVXS-101) Market by Country, 2018 - 2021, USD Million
TABLE 28 North America Zolgensma (AVXS-101) Market by Country, 2022 - 2028, USD Million
TABLE 29 North America Evrysdi Market by Country, 2018 - 2021, USD Million
TABLE 30 North America Evrysdi Market by Country, 2022 - 2028, USD Million
TABLE 31 North America Others Market by Country, 2018 - 2021, USD Million
TABLE 32 North America Others Market by Country, 2022 - 2028, USD Million
TABLE 33 North America Gene Therapy Market by Country, 2018 - 2021, USD Million
TABLE 34 North America Gene Therapy Market by Country, 2022 - 2028, USD Million
TABLE 35 North America Spinal Muscular Atrophy Treatment Market by Country, 2018 - 2021, USD Million
TABLE 36 North America Spinal Muscular Atrophy Treatment Market by Country, 2022 - 2028, USD Million
TABLE 37 US Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
TABLE 38 US Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
TABLE 39 US Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
TABLE 40 US Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
TABLE 41 US Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 42 US Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 43 US Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
TABLE 44 US Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
TABLE 45 US Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 46 US Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 47 Canada Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
TABLE 48 Canada Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
TABLE 49 Canada Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
TABLE 50 Canada Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
TABLE 51 Canada Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 52 Canada Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 53 Canada Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
TABLE 54 Canada Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
TABLE 55 Canada Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 56 Canada Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 57 Mexico Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
TABLE 58 Mexico Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
TABLE 59 Mexico Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
TABLE 60 Mexico Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
TABLE 61 Mexico Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 62 Mexico Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 63 Mexico Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
TABLE 64 Mexico Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
TABLE 65 Mexico Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 66 Mexico Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 67 Rest of North America Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
TABLE 68 Rest of North America Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
TABLE 69 Rest of North America Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
TABLE 70 Rest of North America Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
TABLE 71 Rest of North America Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 72 Rest of North America Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 73 Rest of North America Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
TABLE 74 Rest of North America Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
TABLE 75 Rest of North America Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 76 Rest of North America Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 77 Key Information – PTC Therapeutics, Inc.
TABLE 78 key information – F. Hoffmann-La Roche Ltd.
TABLE 79 Key Information – Biohaven Pharmaceutical Holding Company Ltd.
TABLE 80 Key Information – Novartis AG
TABLE 81 Key information – Ionis Pharmaceuticals, Inc.
TABLE 82 Key Information – Scholar Rock, Inc.
TABLE 83 Key Information – CYTOKINETICS, INCORPORATED
TABLE 84 key information – Astellas Pharma, Inc.
TABLE 85 Key Information – Biogen, Inc.
TABLE 86 Key Information – nmd pharma a/s
List of Figures
FIG 1 Methodology for the research
FIG 2 Recent strategies and developments: PTC Therapeutics, Inc.